Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1984 results about "First pass" patented technology

Tunable laser transmitter with internal wavelength grid generators

The present invention provides a continuously tunable external cavity laser (ECL) with a compact form factor and precise tuning to a selected center wavelength of a selected wavelength grid. The ECL may thus be utilized in telecom applications to generate the center wavelengths for any channel on the ITU or other optical grid. The ECL does not require a closed loop feedback. A novel tuning mechanism is disclosed which provides for electrical or mechanical tuning to a known position or electrical parameter, e.g., voltage, current or capacitance, with the required precision in the selected center wavelength arising as a result of a novel arrangement of a grid generator and a channel selector. The grid generator exhibits first pass bands which correspond to the spacing between individual channels of the selected wavelength grid and a finesse which suppresses side band modes of the laser. The channel selector exhibits second pass bands that are wider than the first pass bands. In an embodiment of the invention the second pass bands have a periodicity substantially corresponding with the separation between the shortest wavelength channel and the longest wavelength channel of the selected wavelength grid and a finesse which suppresses channels adjacent to the selected channel. The broad second pass bands of the channel selector reduce the sensitivity of the ECL to tuning variations about the selected channel, thus avoiding the requirement of a closed loop feedback system to control the channel selector.
Owner:NEWPORT CORP

Speech recognition system to selectively utilize different speech recognition techniques over multiple speech recognition passes

Method and apparatus for multi-pass speech recognition. An input device receives spoken input. A processor performs a first pass speech recognition technique on the spoken input and forms first pass results. The first pass results include a number of alternative speech expressions, each having an assigned score related to the certainty that the corresponding expression correctly matches the spoken input. The processor selectively performs a second pass speech recognition technique on the spoken input according to the first pass results. Preferably, the second pass attempts to correctly match the spoken input to only those expressions which were identified during the first pass. Otherwise, if one of the expressions identified by the first pass is assigned a score higher than a predetermined threshold (e.g., 95%), the second pass is not performed. Because the second pass is performed only when necessary, the invention recognizes speech with a faster average speed for a given accuracy in comparison to prior systems. Alternately, the first pass results identify a characteristic of the spoken input. The characteristic can be the gender of the speaker or a type of telephone the speaker is calling from. In which case, the second pass speech recognition technique is selected from a plurality of speech recognition techniques according to the characteristic identified by the first pass. Because the selected second pass technique is specific to the characteristic of the spoken input, the second pass technique can perform speech recognition faster for a given accuracy than a technique which is not specific.
Owner:NUANCE COMM INC

Modified release compositions of milnacipran

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.
Owner:COLLEGIUM PHARMA INC

Cardiovascular imaging and functional analysis system

A cardiovascular imaging and functional analysis system and method is disclosed, wherein a dedicated fast, sensitive, compact and economical imaging gamma camera system that is especially suited for heart imaging and functional analysis is employed. The cardiovascular imaging and functional analysis system of the present invention can be used as a dedicated nuclear cardiology small field of view imaging camera. The disclosed cardiovascular imaging system and method has the advantages of being able to image physiology, while offering an inexpensive and portable hardware, unlike MRI, CT, and echocardiography systems.The cardiovascular imaging system of the invention employs a basic modular design suitable for cardiac imaging with one of several radionucleide tracers. The detector can be positioned in close proximity to the chest and heart from several different projections, making it possible rapidly to accumulate data for first-pass analysis, positron imaging, quantitative stress perfusion, and multi-gated equilibrium pooled blood (MUGA) tests..In a preferred embodiment, the Cardiovascular Non-Invasive Screening Probe system can perform a novel diagnostic screening test for potential victims of coronary artery disease. The system provides a rapid, inexpensive preliminary indication of coronary occlusive disease by measuring the activity of emitted particles from an injected bolus of radioactive tracer. Ratios of this activity with the time progression of the injected bolus of radioactive tracer are used to perform diagnosis of the coronary patency (artery disease).
Owner:NORTH COAST IND INC

Method and apparatus for generating a quantisation matrix that can be used for encoding an image or a picture sequence

A significant data rate reduction effect in video coding is acchieved by quantizing the transformed frequency coefficients or components of a pixel block so that thereafter fewer amplitude levels need to be encoded and part of the quantised amplitude values becomes zero and need not be encoded as quantised amplitude values. Many transform based video coding standards use a default quantization matrix to achieve better subjective video coding/de-coding quality. A quantization matrix assigns smaller scaling values to some frequency components of the block if the related horizontal and/or vertical frequencies are believed to be the less important frequency components with respect to the resulting subjective picture quality. The inventive quantization matrix generation starts from default quantization matrices and derives therefrom a perceptually optimum quantization matrix for a given picture sequence. In a first pass the candidate quantization matrix for a given picture sequence is iteratively constructed by simultaneously increasing scaling values for some coefficient positions and decreasing scaling values for other ones of the coefficient positions. In a second pass the generated quantization matrix is applied for re-encoding the picture sequence.
Owner:THOMSON LICENSING SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products